SERUM PROSTATIC ACID PHOSPHATASE (PAP) AND PROSTATIC SPECIFIC ANTIGEN (PSA) FOR DETECTION AND MONITORING RECURRENT PROSTATE CANCER

1991 ◽  
Vol 16 (3) ◽  
pp. 221
Author(s):  
L. R. Witherspoon ◽  
J. C. Winters ◽  
S. E. Shuler ◽  
H. A. Fuselier ◽  
H. Neely ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Acid Phosphatase ◽  
Specific Antigen ◽  
Prostatic Acid Phosphatase ◽  
Prostatic Specific Antigen ◽  
Recurrent Prostate Cancer

Clinical Utility of Prostatic Specific Antigen and Prostatic Acid Phosphatase Serum Levels in Monitoring Prostate Cancer

1988 ◽  
Vol 3 (1) ◽  
pp. 23-28 ◽  
Author(s):  
J. Morote ◽  
A. Ruibal ◽  
J. Palou ◽  
J. A. de Torres ◽  
A. Soler-Roselló
Keyword(s):  
Prostate Cancer ◽  
Acid Phosphatase ◽  
Specific Antigen ◽  
Prostatic Acid Phosphatase ◽  
Serum Levels ◽  
Response To Treatment ◽  
Prostatic Specific Antigen ◽  
Serum Samples ◽  
Better Than

We analysed 696 prostatic specific antigen (PSA) and prostatic acid phosphatase (PAP) serum samples by double antibody radioimmunoassay (RIA) I125 in the follow-up of 122 patients with prostate cancer under treatment. PSA levels were significantly correlated to response to treatment, whereas PAP results did not differentiate patients with partial or complete remission. Progression of the disease was detected in 95.2 and 85.4% of PSA and PAP samples, and increased to 99.9% using both simultaneously. On the whole, PSA was better than PAP in monitoring prostate cancer, and the efficacy was greater using both markers together.

Clinical Behaviour of Prostatic Specific Antigen and Prostatic Acid Phosphatase: A Comparative Study

1989 ◽  
Vol 4 (2) ◽  
pp. 87-94 ◽  
Author(s):  
J. Morote Robles ◽  
A. Ruibal Morell ◽  
J.A. De Torres Mateos ◽  
A. Soler Roselló
Keyword(s):  
Acid Phosphatase ◽  
False Positive ◽  
Normal Limit ◽  
Specific Antigen ◽  
Benign Prostatic Hypertrophy ◽  
Prostatic Acid Phosphatase ◽  
Serum Levels ◽  
Prostatic Hypertrophy ◽  
Prostatic Specific Antigen ◽  
Positive Results

We assayed prostatic specific antigen (PSA) and prostatic acid phosphatase (PAP) serum levels in 1383 patients using a double antibody radioimmunoassay (RIA) I125. Establishing the upper normal limit in 10 ng/ml PSA and 2.5 ng/ml for PAP, the false positive results were only 1.9 and 5.1 percent in men with non-prostatic benign or malignant pathology and respectively 0 and 2.2 percent in women. We detected false positive levels for these two tumoral markers in 3.5 and 4.7 percent of patients with non-complicated benign prostatic hypertrophy, 64.8 and 19.2 percent in complicated benign prostatic hypertrophy, 24 and 16 percent in acute prostatitis and 3.3 percent in chronic prostatitis. The sensitivity in patients with prostate cancer was 87.2 percent for PSA and 64.1 percent for PAP, and there was a better correlation with PSA than PAP for tumoral spread and histological grading. Finally, clinical efficacy was higher with PSA and was no better when both markers were assayed.

Sign in / Sign up

Export Citation Format

Share Document